

**Claims**

- 5 1. A crystal of a polypeptide comprising the Ig1-2-3 module of NCAM, said polypeptide comprising amino acid residues 1 to 289 of SEQ ID NO: 44, wherein said crystal comprises atoms arranged in a spatial relationship represented by the structure co-ordinates of Table 2 (Figure 2) or by coordinates having a root mean square deviation therefrom of not more than 2.5 Å.
- 10 2. The crystal according to claim 11, wherein the polypeptide consists of amino acid residues 1 to 289 of SEQ ID NO: 44 and an extra amino acid sequence of 1 to 4 amino acids residues.
- 15 3. The crystal according to claim 11, wherein said crystal diffracts X-rays for determination of atomic co-ordinates to a resolution of at least 4 Å.
4. The crystal according to claim 11, wherein the crystal effectively diffracts X-rays for the determination of the atomic coordinates to a resolution at most 5.0 Å.
- 20 5. The crystal according to claims 14 or 15, wherein the crystal effectively diffracts X-rays for the determination of the atomic coordinates to a resolution 1.5 Å.
6. The crystal according to claim 11, wherein said crystal has unit cell dimensions of  $a=51.5$  Å,  $b=108.5$  Å,  $c=149.0$  Å,  $\alpha=90^\circ$ ,  $\beta=90^\circ$ ,  $\gamma=90^\circ$ .
- 25 7. A method for selecting a candidate compound capable of modulating differentiation, adhesion and/or survival of NCAM presenting cells by modulating the interaction of
- 30 i) the Ig1 module of one individual NCAM molecule with the Ig3 module of another individual NCAM molecule, and/or
- ii) the Ig2 module of one individual NCAM molecule with the Ig3 module of another individual NCAM molecule, and/or
- iii) the Ig2 module of one individual NCAM molecule with the Ig2 module of another individual NCAM molecule,
- 35 said method comprising the steps of
- a) providing a crystalline polypeptide according to claim 1,

P810 PC00

Claims amended in response to Written Opinion of the IPEA  
dated 17 January 2006

2

- b) generating a structural model of the Ig1-2-3 module of NCAM of  
(a) by using the computer modelling techniques;
- c) in-silico evaluating compounds for the capability of
- i) binding to the Ig1 module of NCAM at the NCAM homophilic binding site  
composed of the Ig1, Ig2 and Ig3 modules, and thereby mimicking and/or  
modulating the interaction between the Ig1 and Ig3 modules of NCAM,  
wherein said modules are from two individual NCAM molecules, and/or
- ii) binding to the Ig3 module of NCAM at the NCAM homophilic binding site  
composed of the Ig1, Ig2 and Ig3 modules, and thereby mimicking and/or  
modulating the interaction between the Ig3 and Ig1 modules of NCAM,  
wherein said modules are from two individual NCAM molecules, and/or
- iii) binding to the Ig2 module of NCAM at the NCAM homophilic binding site  
composed of the Ig1, Ig2 and Ig3 modules, and thereby mimicking the  
interaction between Ig2 and Ig3 modules of NCAM, wherein said  
modules are from two individual NCAM molecules, and/or
- iv) binding to the Ig3 module of NCAM at the NCAM homophilic binding site  
composed of the Ig1, Ig2 and Ig3 modules, and thereby mimicking and/or  
modulating the binding between the Ig3 and Ig2 modules of NCAM,  
wherein said modules are from two individual NCAM molecules, and/or
- v) binding to the Ig2 module of NCAM at the NCAM homophilic binding site  
composed of the Ig1, Ig2 and Ig3 modules, and thereby mimicking and/or  
modulating the interaction between the Ig2 and Ig2 modules of NCAM,  
wherein said modules are from two individual NCAM molecules,
- by using the structural model of the Ig1-2-3 module of NCAM of (b);
- d) selecting a candidate compound capable of at least one  
interaction of (c), and
- e) testing the candidate compound of (d) in an in vitro assay for  
the capability of modulating differentiation, adhesion and/or  
survival of NCAM presenting cells, said assays comprising at  
least one NCAM presenting cell, and /or
- f) testing the candidate compound of (d) in an assay comprising  
evaluating the capability of the compound of at least one  
interaction of (b) by contacting the compound with at least one  
individual fragment of an NCAM molecule, said fragment  
comprising a sequence of consecutive amino acid residues

corresponding to the sequence of the Ig1-2-3 module of NCAM comprising residues 1 to 289 of the sequence set forth in SEQ ID NO: 44.

- 5 8. A compound capable of binding to the NCAM homophylic binding site composed of the Ig1, Ig2 and Ig3 modules, wherein said compound is capable of
- 10 i) binding to the Ig1 module of NCAM at said NCAM homophylic binding site, and thereby mimicking and/or modulating the interaction between the Ig1 and Ig3 modules of NCAM, wherein said modules are from two individual NCAM molecules of opposing contacting cells, and/or
- 15 ii) binding to the Ig3 module of NCAM at said NCAM homophylic binding site, and thereby mimicking and/or modulating the interaction between the Ig3 and Ig1 modules of NCAM, wherein said modules are from two individual NCAM molecules of opposing contacting cells, and/or
- 20 iii) binding to the Ig2 module of NCAM at said NCAM homophylic binding site, and thereby mimicking the interaction between Ig2 and Ig3 modules of NCAM, wherein said modules are from two individual NCAM molecules of opposing contacting cells, and/or
- 25 iv) binding to the Ig3 module of NCAM at said NCAM homophylic binding site, and thereby mimicking and/or modulating the binding between the Ig3 and Ig2 modules of NCAM, wherein said modules are from two individual NCAM molecules of opposing contacting cells, and/or
- 30 v) binding to the Ig2 module of NCAM at said NCAM homophylic binding site, and thereby mimicking and/or modulating the interaction between the Ig2 and Ig2 modules of NCAM, wherein said modules are from two individual NCAM molecules of opposing contacting cells,
- said compound being a peptide sequence identified as SEQ ID NO: 1, 2, 3, 4, 7, 10, 11, 12, 13, 14, 16, 17, 18, 40 or 41, or being a fragment or a variant of said sequence, wherein said peptide sequence is selected by the method according to claim: 20.
9. The compound according to claim 8, said compound having the amino acid sequence WFSPNGEKLSPNQ (SEQ ID NO: 1).

P810 PC00

Claims amended in response to Written Opinion of the IPEA  
dated 17 January 2006

4

10. The compound according to claim 8, said compound having the amino acid sequence YKCVTAEDGTQSE (SEQ ID NO: 2).

11. The compound according to claim 8, said compound having the amino acid sequence TLVADADGFPEP (SEQ ID NO: 3).

12. The compound according to claim 8, said compound having the amino acid sequence QIRGIKKTG (SEQ ID NO: 4).

13. The compound according to claim 8, said compound having the amino acid sequence DVR (SEQ ID NO: 5).

14. The compound according to claim 8, said compound having the amino acid sequence RGIKKTG (SEQ ID NO: 6).

15. The compound according to claim 8, said compound having the amino acid sequence DVRRGIKKTG (SEQ ID NO: 7).

16. The compound according to claim 8, said compound having the amino acid sequence KEGED (SEQ ID NO: 8).

17. The compound according to claim 8, said compound having the amino acid sequence IRGIKKTG (SEQ ID NO: 9).

18. The compound according to claim 8, said compound having the amino acid sequence KEGEDGIRGIKKTG (SEQ ID NO: 10).

19. The compound according to claim 8, said compound having the amino acid sequence DKNDE (SEQ ID NO: 11).

20. The compound according to claim 8, said compound having the amino acid sequence TVQARNSIVNAT (SEQ ID NO: 12).

21. The compound according to claim 8, said compound having the amino acid sequence SIHLKVFAK (SEQ ID NO: 13).

22. The compound according to claim 8, said compound having the amino acid sequence LSNNYLQIR (SEQ ID NO: 14).

5 23. The compound according to claim 8, said compound having the amino acid sequence RFIVLSNNYLQI (SEQ ID NO: 15).

24. The compound according to claim 8, said compound having the amino acid sequence KKDVRFIVLSNNYLQI (SEQ ID NO: 16).

10 25. The compound according to claim 8, said compound having the amino acid sequence QEFKEGEDAVIV (SEQ ID NO: 17).

15 26. The compound according to claim 8, said compound having the amino acid sequence KEGEDAVIVCD (SEQ ID NO: 18).

27. The compound according to claim 8, said compound having the amino acid sequence AFSPNGEKLSPNQ (SEQ ID NO: 40).

20 28. The compound according to claim 8, said compound having the amino acid sequence AKSVVTAEDGTQSE (SEQ ID NO: 41).

25 29. Use of one or more compounds as defined in any of the claims 8-28 for the manufacture of a medicament for treatment of a disease wherein modulating differentiation, adhesion, and/or survival of NCAM presenting cells is essential for the treatment.

30 30. The use of claim 29, wherein the medicament is for treating normal, degenerated or damaged NCAM presenting cells.

31. The use of claim 29, wherein the medicament is for treatment comprising the stimulation of differentiation and/or survival of NCAM presenting cells.

32. The use of claim 29, wherein the medicament is for treating the diseases and conditions of the central and peripheral nervous system, or of the muscles or of various organs.

5 33. The use of claim 29, wherein the medicament is for treating the diseases or conditions of the central and peripheral nervous system, such as postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibers, postischaemic damage, e.g. resulting from a stroke, Parkinson's disease, Alzheimer's disease, Huntington's disease, dementias such as multiinfarct  
10 dementia, sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting the circadian clock or neuro-muscular transmission, and schizophrenia, mood disorders, such as manic depression; for treatment of diseases or conditions of the muscles including conditions with impaired function of neuro-muscular connections, such as after organ transplantation, or such as  
15 genetic or traumatic atrophic muscle disorders; or for treatment of diseases or conditions of various organs, such as degenerative conditions of the gonads, of the pancreas such as diabetes mellitus type I and II, of the kidney such as nephrosis and of the heart, liver and bowel.

20 34. The use of claim 29, wherein the medicament is for treating the postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibers, postischaemic, e.g. resulting from a stroke, Parkinson's disease, Alzheimer's disease, dementias such as multiinfarct dementia, sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting the circadian clock or  
25 neuro-muscular transmission, and schizophrenia, mood disorders, such as manic depression.

35. The use of claim 29, wherein the medicament is for promoting the wound-healing.

30

36. The use of claim 29, wherein the medicament is for treating the cancer.

37. The use of claim 29, wherein the medicament is for preventing the cell death of heart muscle cells, such as after acute myocardial infarction, or after  
35 angiogenesis.

P810 PC00

Claims amended in response to Written Opinion of the IPEA  
dated 17 January 2006

7

38. The use of claim 29, wherein the medicament is for promoting the revascularisation.

5 39. The use of claim 29, wherein the medicament is for stimulating the ability to learn and/or of the short and/or long-term memory.

10 40. Use of a crystal of the Ig1-2-3 module of NCAM according to claims 1-6 for the in-silico screening a candidate compound capable of modulating NCAM homophilic adhesion-dependent neural plasticity, cell differentiation and/or survival.

15 41. A pharmaceutical composition comprising one or more compounds as defined in any of the claims 8-28.